Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.19 USD | -0.45% |
|
-14.79% | -31.13% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.13% | 17.86M | |
+35.14% | 51.07B | |
-7.43% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+11.63% | 26.35B | |
-17.77% | 19.46B | |
+40.52% | 13.58B | |
+30.70% | 12.46B | |
-3.41% | 11.75B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Insider Buy: Lumos Pharma